Hirst B H, Holland J, Marr A P, Parsons M E, Sanders D J
J Physiol. 1984 Dec;357:441-52. doi: 10.1113/jphysiol.1984.sp015510.
The gastric-acid secretory potency of gastrin peptides was investigated in vivo, in conscious cats prepared with gastric fistula, and in vitro, with kitten isolated gastric mucosae. The influence of peptide length on potency was investigated by comparing synthetic human gastrin heptadecapeptide, non-sulphate (shG17ns) with a synthetic gastrin butyloxycarbonyl hexapeptide (G6ns), and the influence of sulphation by comparison of G6ns with its sister sulphated peptide (G6s). When exogenous doses were compared, shG17ns was the most potent peptide (mean exogenous dose for half-maximal stimulation (EDe50) : 0.33 nmol kg-1 h-1), and was 15.8 times more potent than G6ns (EDe50:5.14 nmol kg-1 h-1). This potency ratio was reduced to 9.4 when circulating immunoreactive concentrations of the two peptides were compared (mean circulating concentration for half-maximal stimulation (EDc50) : shG17ns, 201 pM; G6ns, 1890 pM). The greater potency ratio when exogenous doses were compared was due to the greater metabolic clearance rate (m.c.r.) of the shorter gastrin (m.c.r.: shG17ns, 37 ml kg-1 min-1; G6ns, 121 ml kg-1 min-1). In vitro, shG17ns (mean concentration for half-maximal stimulation (EC50) : 1.99 nM) was 2.8 times more potent than G6ns (EC50: 5.57 nM). Sulphation of the hexapeptide increased its potency 3.6-fold when exogenous doses were compared (EDe50 G6s: 1.42 nmol kg-1 h-1). The greater potency of the sulphated peptide appeared to be due to its lower m.c.r. (20 ml kg-1 min-1), and was eliminated when circulating concentrations were compared; potency ratio G6ns: G6s, 1.1. We conclude that the increased potency of short gastrin peptides observed upon sulphation is likely to be due to increased resistance to metabolic clearance. Part of the increased potency observed with increasing peptide length can also be explained by increased resistance to clearance, but the small potency difference in vitro may reflect greater affinity for gastrin receptors.
在体内对胃泌素肽的胃酸分泌能力进行了研究,实验对象是制备了胃瘘的清醒猫,同时也在体外使用新生小猫分离的胃黏膜进行了研究。通过比较合成的人胃泌素十七肽(非硫酸盐形式,shG17ns)与合成的胃泌素丁氧羰基六肽(G6ns),研究了肽长度对活性的影响;通过比较G6ns与其硫酸化肽姐妹(G6s),研究了硫酸化的影响。当比较外源性剂量时,shG17ns是活性最强的肽(半数最大刺激的平均外源性剂量(EDe50):0.33 nmol kg-1 h-1),其活性比G6ns高15.8倍(EDe50:5.14 nmol kg-1 h-1)。当比较两种肽的循环免疫反应浓度时,该活性比降至9.4(半数最大刺激的平均循环浓度(EDc50):shG17ns,201 pM;G6ns,1890 pM)。比较外源性剂量时活性比更高是由于较短胃泌素的代谢清除率(m.c.r.)更高(m.c.r.:shG17ns,37 ml kg-1 min-1;G6ns,121 ml kg-1 min-1)。在体外,shG17ns(半数最大刺激的平均浓度(EC50):1.99 nM)的活性比G6ns高2.8倍(EC50:5.57 nM)。比较外源性剂量时,六肽的硫酸化使其活性提高了3.6倍(G6s的EDe50:1.42 nmol kg-1 h-1)。硫酸化肽活性更高似乎是由于其较低的m.c.r.(20 ml kg-1 min-1),而比较循环浓度时这种差异消失了;G6ns与G6s的活性比为1.1。我们得出结论,硫酸化后短胃泌素肽活性增加可能是由于对代谢清除的抗性增加。随着肽长度增加观察到的活性增加部分也可以用对清除的抗性增加来解释,但体外较小的活性差异可能反映了对胃泌素受体的亲和力更高。